PortfoliosLab logoPortfoliosLab logo
VKTX vs. NVAX
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

VKTX vs. NVAX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Viking Therapeutics, Inc. (VKTX) and Novavax, Inc. (NVAX). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, VKTX achieves a -18.68% return, which is significantly lower than NVAX's 34.37% return. Over the past 10 years, VKTX has outperformed NVAX with an annualized return of 36.76%, while NVAX has yielded a comparatively lower -23.23% annualized return.


VKTX

1D
3.10%
1M
-8.65%
YTD
-18.68%
6M
-23.11%
1Y
-1.17%
3Y*
6.42%
5Y*
36.31%
10Y*
36.76%

NVAX

1D
5.49%
1M
-6.13%
YTD
34.37%
6M
34.98%
1Y
27.36%
3Y*
5.09%
5Y*
-46.69%
10Y*
-23.23%
*Multi-year figures are annualized to reflect compound growth (CAGR)

VKTX vs. NVAX - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
VKTX
Viking Therapeutics, Inc.
-18.68%-12.57%116.23%97.98%104.35%-18.29%-29.80%4.84%88.42%241.18%
NVAX
Novavax, Inc.
34.37%-16.42%67.50%-53.31%-92.81%28.30%2,701.76%-89.18%48.39%-1.59%

Correlation

The correlation between VKTX and NVAX is 0.31, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.31

Correlation (3Y)
Calculated over the trailing 3-year period

0.26

Correlation (5Y)
Calculated over the trailing 5-year period

0.29

Correlation (10Y)
Calculated over the trailing 10-year period

0.27

Correlation (All Time)
Calculated using the full available price history since Apr 29, 2015

0.24

Fundamentals

Market Cap

VKTX:

$3.31B

NVAX:

$1.47B

EPS

VKTX:

-$4.16

NVAX:

-$0.52

Total Revenue (TTM)

VKTX:

$0.00

NVAX:

$596.34M

Gross Profit (TTM)

VKTX:

-$208.00K

NVAX:

$504.72M

EBITDA (TTM)

VKTX:

-$501.77M

NVAX:

-$57.01M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

VKTX vs. NVAX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VKTX
VKTX Risk / Return Rank: 4444
Overall Rank
VKTX Sharpe Ratio Rank: 4343
Sharpe Ratio Rank
VKTX Sortino Ratio Rank: 4545
Sortino Ratio Rank
VKTX Omega Ratio Rank: 4848
Omega Ratio Rank
VKTX Calmar Ratio Rank: 4242
Calmar Ratio Rank
VKTX Martin Ratio Rank: 4242
Martin Ratio Rank

NVAX
NVAX Risk / Return Rank: 5959
Overall Rank
NVAX Sharpe Ratio Rank: 5858
Sharpe Ratio Rank
NVAX Sortino Ratio Rank: 6161
Sortino Ratio Rank
NVAX Omega Ratio Rank: 5757
Omega Ratio Rank
NVAX Calmar Ratio Rank: 6161
Calmar Ratio Rank
NVAX Martin Ratio Rank: 5959
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VKTX vs. NVAX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Viking Therapeutics, Inc. (VKTX) and Novavax, Inc. (NVAX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


VKTXNVAXDifference
Sharpe ratioReturn per unit of total volatility

-0.41

Sortino ratioReturn per unit of downside risk

-0.63

Omega ratioGain probability vs. loss probability

1.08

1.13

-0.05

Calmar ratioReturn relative to maximum drawdown

-0.03

0.76

-0.79

Martin ratioReturn relative to average drawdown

-0.05

1.49

-1.54

VKTX vs. NVAX - Sharpe Ratio Comparison

The current VKTX Sharpe Ratio is -0.02, which is lower than the NVAX Sharpe Ratio of 0.40. The chart below compares the historical Sharpe Ratios of VKTX and NVAX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

VKTX vs. NVAX - Drawdown Comparison

The maximum VKTX drawdown since its inception was -90.41%, smaller than the maximum NVAX drawdown of -98.82%. Use the drawdown chart below to compare losses from any high point for VKTX and NVAX.


Loading charts...

Drawdown Indicators


VKTXNVAXDifference

Max Drawdown

Largest peak-to-trough decline

-90.41%

-98.82%

+8.41%

Max Drawdown (1Y)

Largest decline over 1 year

-45.14%

-35.94%

-9.20%

Max Drawdown (3Y)

Largest decline over 3 years

-78.86%

-74.11%

-4.75%

Max Drawdown (5Y)

Largest decline over 5 years

-78.86%

-98.61%

+19.75%

Max Drawdown (10Y)

Largest decline over 10 years

-89.26%

-98.82%

+9.56%

Current Drawdown

Current decline from peak

-69.72%

-97.18%

+27.46%

Average Drawdown

Average peak-to-trough decline

-60.01%

-70.76%

+10.75%

Ulcer Index

Depth and duration of drawdowns from previous peaks

22.80%

18.46%

+4.34%

Volatility

VKTX vs. NVAX - Volatility Comparison

The current volatility for Viking Therapeutics, Inc. (VKTX) is 15.32%, while Novavax, Inc. (NVAX) has a volatility of 23.98%. This indicates that VKTX experiences smaller price fluctuations and is considered to be less risky than NVAX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


VKTXNVAXDifference

Volatility (1M)

Calculated over the trailing 1-month period

15.32%

23.98%

-8.66%

Volatility (6M)

Calculated over the trailing 6-month period

40.84%

52.24%

-11.40%

Volatility (1Y)

Calculated over the trailing 1-year period

74.00%

68.90%

+5.10%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

101.60%

106.10%

-4.50%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

97.02%

115.50%

-18.48%

Dividends

VKTX vs. NVAX - Dividend Comparison

Neither VKTX nor NVAX has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

VKTX vs. NVAX - Financials Comparison

This section allows you to compare key financial metrics between Viking Therapeutics, Inc. and Novavax, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


-500.00M0.00500.00M202220232024202520260
139.51M
(VKTX) Total Revenue
(NVAX) Total Revenue
Values in USD except per share items

Frequently Asked Questions


VKTX and NVAX have a correlation of 0.31, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

NVAX has higher volatility (23.98%) compared to VKTX (15.32%). In terms of maximum drawdown, VKTX dropped -90.41% vs NVAX's -98.82%.

NVAX currently has the higher Sharpe Ratio (0.40 vs -0.02), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for VKTX and NVAX

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer